Zacks Investment Research
05 Aug 2026, 16:51 UTC · 1h ago
ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 16:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Zimmer Biomet Holdings (ZBH) reported Q2 2026 adjusted EPS of $2.07, beating the Zacks Consensus Estimate of $2.01. — An earnings beat typically provides positive short-term momentum for a stock's price.
+0.30ZBH net sales reached $2.18 billion, surpassing the Zacks Consensus Estimate of $2.13 billion. — Revenue growth and a beat on top-line estimates indicate healthy demand for the company's products.
+0.20The 'Technology & Data, Bone Cement and Surgical' business unit saw a significant revenue surge of 21.1% to $199.4 million. — Strong growth in a specific high-tech segment suggests a competitive advantage and potential for future scaling.
+0.20Continue reading
6 related stories
Top 2 movers · tap to explore
ZBH reported organic constant-currency sales growth of 4% for the quarter. — Organic growth provides a clearer picture of underlying business health by removing acquisition and currency noise.
Which stocks this story touches
The company beat both earnings and revenue estimates for the second quarter, leading to a rise in pre-market stock price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
